SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 101 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,713,345 | +16.7% | 117,999 | +68.2% | 0.00% | 0.0% |
| Q2 2023 | $1,468,302 | -39.9% | 70,153 | -39.4% | 0.00% | -33.3% |
| Q1 2023 | $2,443,373 | +72.0% | 115,690 | +107.3% | 0.00% | +50.0% |
| Q4 2022 | $1,420,415 | -99.9% | 55,812 | -15.8% | 0.00% | -33.3% |
| Q3 2022 | $1,592,636,000 | +556.3% | 66,277 | +425.5% | 0.00% | – |
| Q2 2022 | $242,655,000 | -63.1% | 12,612 | -66.7% | 0.00% | -100.0% |
| Q1 2022 | $657,989,000 | -56.1% | 37,859 | -44.6% | 0.00% | -50.0% |
| Q4 2021 | $1,497,254,000 | +637.8% | 68,399 | +544.1% | 0.00% | – |
| Q3 2021 | $202,948,000 | +279.1% | 10,620 | +240.6% | 0.00% | – |
| Q2 2021 | $53,536,000 | -79.6% | 3,118 | -73.5% | 0.00% | – |
| Q1 2021 | $262,663,000 | -87.5% | 11,747 | -87.6% | 0.00% | -100.0% |
| Q4 2020 | $2,106,573,000 | +2176.6% | 94,720 | +1410.9% | 0.00% | – |
| Q3 2020 | $92,530,000 | +197.6% | 6,269 | +198.8% | 0.00% | – |
| Q2 2020 | $31,092,000 | -56.1% | 2,098 | -67.5% | 0.00% | – |
| Q1 2020 | $70,746,000 | +189.0% | 6,449 | +131.3% | 0.00% | – |
| Q4 2019 | $24,479,000 | +28.4% | 2,788 | +9.2% | 0.00% | – |
| Q3 2019 | $19,063,000 | +24.2% | 2,552 | +54.9% | 0.00% | – |
| Q2 2019 | $15,343,000 | -7.6% | 1,648 | -47.9% | 0.00% | – |
| Q1 2019 | $16,600,000 | +924.7% | 3,162 | +768.7% | 0.00% | – |
| Q4 2018 | $1,620,000 | -55.5% | 364 | -19.3% | 0.00% | – |
| Q3 2018 | $3,644,000 | -26.9% | 451 | -36.5% | 0.00% | – |
| Q2 2018 | $4,984,000 | -86.0% | 710 | -71.7% | 0.00% | – |
| Q1 2018 | $35,660,000 | +64.5% | 2,506 | +1.3% | 0.00% | – |
| Q4 2017 | $21,672,000 | +182.4% | 2,474 | +277.1% | 0.00% | – |
| Q3 2017 | $7,675,000 | +14.9% | 656 | +37.2% | 0.00% | – |
| Q2 2017 | $6,678,000 | +5329.3% | 478 | +5211.1% | 0.00% | – |
| Q1 2017 | $123,000 | -73.6% | 9 | -86.2% | 0.00% | – |
| Q4 2016 | $466,000 | -90.4% | 65 | -79.8% | 0.00% | – |
| Q3 2016 | $4,866,000 | +165.6% | 321 | +72.6% | 0.00% | – |
| Q2 2016 | $1,832,000 | – | 186 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |